Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: A retrospective population-based study from the Nordic Lymphoma Group

Annals of Oncology

Volumn 24, Issue 7, 2013, Pages 1879-1886

  Wasterlid T ^a   Brown, P N ^b   Hagberg, O ^a   Hagberg, H ^c   Pedersen, L M ^d   D'Amore, F ^e   Jerkeman, M ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Rigshospitalet   (Denmark)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d ROSKILDE HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Burkitt lymphoma; Chemotherapy regimen; Rituximab

Indexed keywords

BETAMETHASONE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 84883751931     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt058     Document Type: Article

References (29)

1. Dalla-Favera R, Bregni M, Erikson J et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824-7827.
2. Wasterlid T, Jonsson B, Hagberg H et al. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk Lymphoma 2011; 52: 2090-2096.
3. Kasamon YL, Swinnen LJ. Treatment advances in adult Burkitt lymphoma and leukemia. Curr Opin Oncol 2004; 16: 429-435.
4. Kelly JL, Toothaker SR, Ciminello L et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma 2009; 9: 307-310.
5. Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program 2008; 341-348.
6. Divine M, Casassus P, Koscielny S et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005; 16: 1928-1935.
7. Mead GM, Barrans SL, Qian W et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112: 2248-2260.
8. Thomas DA, Cortes J, O'Brien S et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 2461-2470.
9. Magrath I, Adde M, Shad A et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925-934.
10. Philip T, Meckenstock R, Deconnick E et al. Treatment of poor prognosis Burkitt's lymphoma in adults with the Societe Francaise d'Oncologie Pediatrique LMB Protocol-a study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC). Eur J Cancer 1992; 28A: 1954-1959.
11. Linch DC. Burkitt lymphoma in adults. Br J Haematol 2012; 156: 693-703.
12. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004; 104: 3009-3020.
13. Smeland S, Blystad AK, Kvaloy SO et al. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol 2004; 15: 1072-1078.
14. Lacasce A, Howard O, Lib S et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004; 45: 761-767.
15. Reiter A, Schrappe M, Tiemann M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin- Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999; 94: 3294-3306.
16. Soussain C, Patte C, Ostronoff M et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 85: 664-674.
17. Oriol A, Ribera JM, Bergua J et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 2008; 113: 117-125.
18. Di Nicola M, Carlo-Stella C, Mariotti J et al. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol 2004; 126: 815-820.
19. Lee EJ, Petroni GR, Schiffer CA et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001; 19: 4014-4022.
20. Wilson WH, Grossbard ML, Pittaluga S et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685-2693.
21. Thomas DA, Faderl S, O'Brien S et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569-1580.
22. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007; 8 (Suppl 2): S57-S62.
23. Maruyama D, Watanabe T, Maeshima AM et al. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 2010; 92: 732-743.
24. Barnes JA, Lacasce AS, Feng Y et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol 2011; 22: 1859-1864.
25. Mohamedbhai SG, Sibson K, Marafioti T et al. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. Br J Haematol 2011; 152: 175-181.
26. Abrahamsson A, Dahle N, Jerkeman M. Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Leuk Lymphoma 2011; 52: 1929-1935.
27. Gang AO, Strom C, Pedersen M et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with RCHOP- 14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol 2012; 23: 147-153.
28. Wilson WH, Dunleavy K, Pittaluga S et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008; 26: 2717-2724.
29. Corazzelli G, Frigeri F, Russo F et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. Br J Haematol 2012; 156: 234-244.